Global Biotechnology Market Segmentation, By Product Type (Instruments, Reagents, Services, and Software), Technology (Nano Biotechnology, PCR Technology, DNA Sequencing, Chromatography, Tissue Engineering and Regeneration, Cell-Based Assays, Fermentation, and Others), Application (Bio-pharmacy, Bio-industrial, Bio-services, Bioinformatics, and Bio-agriculture), End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributors, and Others) – Industry Trends and Forecast to 2031
Biotechnology Market Analysis
The biotechnology market is experiencing rapid growth, driven by advancements in genetic engineering, biopharmaceuticals, and agricultural biotechnology. Biotechnology integrates biological systems with advanced technological processes, revolutionizing healthcare, agriculture, and industrial applications. The sector is expanding due to the increasing demand for personalized medicine, growing interest in synthetic biology, and the rising need for innovative drug discovery techniques. Recent developments include advancements in CRISPR gene-editing technologies and increased funding for research in cancer therapies, regenerative medicine, and bio-based products. Key players are investing in R&D to develop cutting-edge solutions, fostering competition and accelerating innovation. The COVID-19 pandemic has further highlighted the significance of biotechnology, with rapid vaccine development demonstrating its transformative potential. With ongoing innovations and government support, the biotechnology market is poised to continue its upward trajectory in the coming years, providing new growth opportunities for industry players across multiple sectors.
Biotechnology Market Size
The global biotechnology market size was valued at USD 1.32 billion in 2023 and is projected to reach USD 10.12 billion by 2031, with a CAGR of 29.00% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Biotechnology Market Trends
“Innovations in Genetic Biopharmaceuticals”
The biotechnology market is evolving rapidly, driven by innovations in genetic engineering, biopharmaceuticals, and bioinformatics. Advances in biotechnology are revolutionizing healthcare, agriculture, and industrial processes, leading to personalized medicine, improved crop yields, and sustainable solutions. One notable trend is the increasing use of CRISPR gene-editing technology, which allows for precise modifications in DNA, facilitating breakthroughs in genetic therapies and disease treatment. The shift towards personalized medicine, where treatments are tailored to an individual's genetic makeup, is also gaining momentum, offering more effective and targeted therapies. With continuous innovations and growing investments in biotech research and development, the industry is set for sustained growth, driving advancements across multiple sectors, including healthcare and agriculture.
Report Scope and Biotechnology Market Segmentation
|
Attributes
|
Biotechnology Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Key Market Players
|
Abbott (U.S.), Agilent Technologies Inc. (U.S.), Danaher Corporation (U.S.), BD (U.S.), Bio-Rad Laboratories Inc. (U.S.), General Electric Company (U.S.), BIOMÉRIEUX (France), Lonza (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Hoefer, Inc. (U.S.), PerkinElmer Inc. (U.S.), Merck KGaA (Germany), Promega Corporation (U.S.), Quality Biological (U.S.), Siemens (Germany), Bio-Techne (U.S.), TAKARA HOLDINGS INC. (Japan), Sysmex Corporation (Japan), QuidelOrtho Corporation (U.S.), Olympus Corporation (Japan)
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Biotechnology Market Definition
Biotechnology is the field of science that applies biological systems, organisms, or derivatives to develop or create products and technologies for various sectors such as healthcare, agriculture, and industry. It harnesses cellular and biomolecular processes to solve problems, improve existing solutions, or innovate new ones. Biotechnology includes techniques like genetic engineering, molecular diagnostics, and fermentation. In healthcare, it is used for drug development, gene therapy, and personalized medicine. In agriculture, it improves crop yields and pest resistance. Industrial applications focus on biofuels, bioplastics, and environmental sustainability.
Biotechnology Market Dynamics
Drivers
- Increasing Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders, is significantly driving the demand for effective therapeutic solutions in the biotechnology market. As these conditions become more widespread, healthcare providers and patients are seeking innovative treatments that can effectively manage symptoms, enhance quality of life, and improve patient outcomes. Biopharmaceuticals and biotechnological advancements are at the forefront of developing targeted therapies and personalized medicine approaches tailored to individual patient needs. This trend is pushing research and development efforts within the biotechnology sector and encouraging collaboration between pharmaceutical companies and research institutions to bring forth new and effective treatment options. Ultimately, the urgent need for effective therapies to combat the rising incidence of chronic diseases serves as a crucial market driver, fostering growth and innovation within the biotechnology landscape.
- Increasing Demand for Personalized Medicine
The movement toward personalized medicine, which tailors treatments based on individual genetic profiles, is significantly influencing the biopharmaceutical market. This shift enables healthcare providers to offer more effective therapies that align with a patient’s unique genetic makeup, increasing the likelihood of positive treatment outcomes. As a result, there is a growing demand for biopharmaceuticals that are specifically designed to target genetic variations, leading to enhanced precision in treatment. Innovations in genomics and biotechnology are facilitating the development of these tailored therapies, further driving research and investment in the sector. In addition, the increasing awareness and acceptance of personalized medicine among healthcare professionals and patients alike is propelling the market forward. This trend underscores the importance of biopharmaceuticals in achieving better patient care and is a key driver of growth within the biotechnology industry.
Opportunities
- Growing Focus on Sustainable Practices
The increasing demand for eco-friendly agricultural solutions is significantly expanding market opportunities within the biotechnology sector. As consumers become more environmentally conscious, there is a growing preference for sustainable farming practices that minimize the use of chemical fertilizers and pesticides. Biotechnology plays a crucial role in this shift by providing innovative solutions such as genetically modified crops that require fewer resources while improving yield and resistance to pests and diseases. Furthermore, biotechnological applications extend beyond agriculture to various industries, including pharmaceuticals, food processing, and waste management, where sustainable practices are gaining traction. As companies seek to reduce their environmental footprint and meet regulatory standards, the integration of biotechnology in developing sustainable solutions presents a lucrative opportunity for growth and innovation in the market.
- Technological Advancements in Biotechnology
Continuous advancements in biotechnology processes and methodologies are significantly enhancing efficiency and productivity in drug development and production, creating substantial market opportunities. Innovations such as high-throughput screening, automated bioprocessing, and artificial intelligence integration streamline research and development workflows, reducing time-to-market for new therapeutics. These improvements allow companies to conduct more extensive testing and optimization of biologics, resulting in higher-quality products and lower production costs. In addition, the emergence of personalized medicine, driven by advancements in genomic and proteomic technologies, is further accelerating drug development, as therapies can now be tailored to individual patient profiles. As biotechnology continues to evolve, these efficiencies benefit pharmaceutical companies and improve patient outcomes, making it a key area for investment and growth in the biotechnology market.
Restraints/Challenges
- Shortage of Skilled Professionals
The biotechnology industry faces a significant challenge due to a growing shortage of skilled professionals, including scientists, engineers, and technicians. This shortage can impede innovation and development within the sector, as companies require a highly specialized workforce to navigate complex research, development, and manufacturing processes. The rapid pace of technological advancements further exacerbates this issue, as existing professionals may lack the necessary training in emerging technologies. In addition, academic programs often struggle to keep up with industry demands, leading to a gap between education and practical application. Without a sufficient pool of qualified talent, the biotechnology sector may experience slowed progress, hindering its ability to address pressing healthcare challenges and fulfill the rising demand for biopharmaceuticals and advanced therapies.
- High Research and Development Costs
The biotechnology sector is characterized by its reliance on substantial investments in research and development (R&D). This high capital requirement can pose a significant barrier to entry for smaller companies and startups looking to innovate within the industry. Unlike larger firms, which may have access to extensive funding and resources, smaller entities often struggle to secure the necessary financial backing to conduct comprehensive R&D. Consequently, this disparity can lead to a lack of competitive advantage, limiting their ability to develop new therapies or technologies. As a result, the overall innovation landscape may be adversely affected, hindering advancements in biotechnology and restricting market growth. This reliance on significant investments in R&D stands as a notable restraint in the biotechnology market.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Biotechnology Market Scope
The market is segmented on the basis of product, technology, application, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Instruments
- Reagents
- Services
- Software
Technology
- Nano Biotechnology
- PCR Technology
- DNA Sequencing
- Chromatography
- Tissue Engineering and Regeneration
- Cell-Based Assays
- Fermentation
- Others
Application
- Bio-pharmacy
- Bio-industrial
- Bio-services
- Bioinformatics
- Bio-agriculture
End User
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academic and Research Institutes
- Others
Distribution Channel
- Direct Tender
- Third Party Distributors
- Others
Biotechnology Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, product, technology, application, end user, and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America holds a dominant position in the biotechnology market, largely due to the growing number of individuals affected by chronic diseases. This rising incidence of conditions such as diabetes, cancer, and heart disease intensifies the demand for innovative biotechnological solutions. In addition, the region's advanced healthcare infrastructure and substantial investment in research and development further support the growth of biotechnology tailored to address these health challenges.
Asia-Pacific region is anticipated to experience the fastest growth in the biotechnology market during the forecast period of 2024 to 2031, driven by the presence of numerous biotechnology product providers. This abundance of companies fosters innovation and competition, enhancing the availability of diverse biotechnological solutions. In addition, increasing investments in research and development and supportive government initiatives further contribute to the region's robust market expansion.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Biotechnology Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Biotechnology Market Leaders Operating in the Market Are:
- Abbott (U.S.)
- Agilent Technologies Inc. (U.S.)
- Danaher Corporation (U.S.)
- BD (U.S.)
- Bio-Rad Laboratories Inc. (U.S.)
- General Electric Company (U.S.)
- BIOMÉRIEUX (France)
- Lonza (Switzerland)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Hoefer, Inc. (U.S.)
- PerkinElmer Inc. (U.S.)
- Merck KGaA (Germany)
- Promega Corporation (U.S.)
- Quality Biological (U.S.)
- Siemens (Germany)
- Bio-Techne (U.S.)
- TAKARA HOLDINGS INC. (Japan)
- Sysmex Corporation (Japan)
- QuidelOrtho Corporation (U.S.)
- Olympus Corporation (Japan)
Latest Developments in Biotechnology Market
- In October 2023, Gilead Sciences, Inc. partnered with Assembly Biosciences to develop innovative therapeutics targeting severe viral diseases. This collaboration aims to leverage both companies' expertise and resources to accelerate the creation of effective treatment options. By combining their strengths, they seek to address critical unmet medical needs in the field of virology and improve patient outcomes
- In October 2023, Kite, a subsidiary of Gilead, entered into a research collaboration and licensing agreement with Epicrispr Biotechnologies. This partnership aims to harness Epic Bio's gene regulation platform to enhance the development of advanced cancer cell therapies. By integrating their innovative technologies, both companies aspire to create more effective treatment options for cancer patients
- In September 2023, Merck KGaA formed partnerships with BenevolentAI and Exscientia to utilize artificial intelligence in the drug discovery process. This collaboration focuses on developing new treatments in oncology, neurology, and immunology, aiming to identify innovative candidates for clinical development. By harnessing advanced AI technologies, Merck KGaA hopes to accelerate the discovery of groundbreaking therapeutic options
- In July 2023, Alexion and AstraZeneca Rare Disease entered into an agreement with Pfizer Inc. to acquire preclinical gene therapy programs. This collaboration reinforces their commitment to advancing next-generation genomic medicines by integrating complementary assets and innovative technologies. By pooling resources, the companies aim to accelerate the development of transformative therapies in the field of gene therapy
- In June 2023, Lonza completed the acquisition of Synaffix B.V., a biotechnology firm focused on enhancing its clinical-stage technology platform for antibody-drug conjugate (ADC) development. Following the acquisition, Synaffix's revenues and profit margins are anticipated to be integrated into Lonza's financial statements from the date of the acquisition. This strategic move aims to bolster Lonza's capabilities in the biopharmaceutical sector and accelerate innovation in ADC technologies
SKU-